marketing-medtech

**Source:** GetYourJob (classified health-software, actively hiring developers)
**Founder:** Jean-Louis Fraysse — Co-founder (industrial pharmacist; co-founder with Olivier Thuillart, biomedical engineer)
**Background:** pharma_medtech_exec | verified: True — Jean-Louis Fraysse is a French industrial pharmacist and chronic-disease / e-health specialist. He spent his career in the pharmaceutical industry (notably as a pharmacist at Sanofi and Boiron laboratories) before co-founding the medtech company BOTdesign in April 2017 together with biomedical engineer Olivier Thuillart. At BOTdesign (a Toulouse-based digital health / medical-device company whose MAX platform is CE-certified as a Medical Device) he is Co-founder and an executive/leader, and he also holds e-health leadership and board roles (e.g. Co-President of SILICA, Vice-President of SoFia Santé, board memberships at ANTADIR and FEDEPSAD). This matches the claimed 'pharma_medtech_exec' profile: a pharma-industry pharmacist turned medtech company executive/co-founder.
**Stage / fundraise:** Seed/early-growth. Founded 2017 in Toulouse, ~10 employees (GetYourJob enrichment May 2026). Commercial traction with MAX/HEKO across ~20 French hospitals/clinics and 100k+ patients reported. / Raised ~€1M in 2020 (Fonds Occitanie Ouest Entrepreneur / M Capital, Toulouse business angels, BPI, Crédit Mutuel, Banque Populaire) to double headcount; ran a WiSEED equity crowdfunding campaign in 2022 to fund national deployment, R&D, and regulatory/reimbursement work. An active WiSEED-style crowdfunding/investment mention still appears on the site.
**Regulatory trigger:** Operates regulated SaMD: MyRisk pre-diagnosis recognized as a medical device; company has been a certified Medical Device manufacturer since 2021 and holds ISO 13485 (medical device QMS). Class likely I/IIa (pre-diagnosis / clinical follow-up decision-support). MDR transition + IEC 62304 software lifecycle + reimbursement pathway are stated company priorities (cited as use of WiSEED funds). Exact MDR class and CE certificate details not published in sources reviewed.
**Email:** jfraysse@botdesign.net (confidence low) — No personal address for the founder is published. The only published addresses are the general contact@botdesign.net and support@botdesign.net (botdesign.net/en/contact-2/). Third-party aggregators report the dominant pattern as {first-initial}{lastname}@botdesign.net (~60%), which yields jfraysse@botdesign.net — INFERRED from pattern, not a confirmed/published address. High-confidence reachable address is contact@botdesign.net.
**LinkedIn:** https://www.linkedin.com/in/dr-jean-louis-fraysse-botdesign/ (company: https://www.linkedin.com/company/botdesign) **Website:** https://botdesign.net
**Score:** 11 -> Tier A
**Hook:** A pharma-founder-led, ~10-person team running ISO 13485-certified SaMD (MAX/HEKO, MyRisk) and pushing national hospital deployment after a €1M raise — yet currently filling engineering capacity with a full-stack intern. OmDev gives Jean-Louis a senior dev team plus a dedicated CTO at a fixed monthly price ~3x cheaper than hiring that team in-house, and the build pipeline emits compliance evidence (signed SOUP register + requirements-to-code-to-test traceability) that feeds straight into their IEC 62304/MDR file — exactly the regulatory load a small clinical-science team struggles to carry while scaling.

---

## Founder & background
Jean-Louis Fraysse co-founded BOTdesign (Toulouse, 2017) with Olivier Thuillart. Fraysse is an industrial pharmacist / e-health & chronic-disease specialist; Thuillart is a biomedical engineer — a clinical-science + medtech founding team, not software founders ([myfrenchstartup](https://www.myfrenchstartup.com/fr/startup-france/197349/botdesign), [Entreprises Occitanie](https://www.entreprises-occitanie.com/actualites/toulouse-avec-botdesign-lintelligence-artificielle-simplifie-la-vie-des-medecins-et-des)).
No finance/insurance background found; classified as pharma/medtech executive. Candidate-note "CTO Frederic" could not be verified online — treat as unconfirmed.

## Funding & momentum
Raised ~€1M in 2020 (Fonds Occitanie Ouest Entrepreneur via M Capital, Toulouse business angels, BPI, Crédit Mutuel, Banque Populaire) explicitly to double the workforce and scale deployment ([press release](https://botdesign.net/en/2022/09/12/press-release-october-2020/)).
Ran a WiSEED equity-crowdfunding campaign (2022) to fund national rollout, R&D and regulatory/reimbursement compliance; site still surfaces a WiSEED investment hook. ~10 employees today (GetYourJob, enriched May 2026).

## Product & regulatory
Products: MAX/HEKO — HDS-hosted clinical chatbot platform for pre-anesthesia consults, pre-diagnosis (MyRisk) and clinical follow-up; ORIGA — deep-learning synthetic/anonymized patient-data platform for clinical studies (partnership with Nextep Health) ([HEKO](https://botdesign.net/en/heko-en/)).
Regulated SaMD: MyRisk is recognized as a medical device, certified medical-device manufacturer since 2021, ISO 13485 QMS. Likely Class I/IIa decision-support; MDR transition, IEC 62304 lifecycle and reimbursement are stated company priorities. Exact MDR class / CE certificate not published in reviewed sources.

## Pain & buying signals
Actively hiring developers (GetYourJob signal): active offer "Stage Dev FullStack e-Santé - Septembre 2026", Toulouse, onsite, posted day 0 — capacity being filled with an intern, not senior engineers, on a ~10-person team.
A small clinical-science-led team carries a heavy regulatory load (ISO 13485, MDR, IEC 62304, reimbursement) while pushing national hospital deployment post-raise — a scale-vs-compliance squeeze. No confirmed QARA/CTO leadership name found publicly.

**Why OmDev fits:** OmDev drops in a senior dev squad + a dedicated CTO at a fixed monthly price ~3x cheaper than building that team in-house — and the OmDev pipeline produces the compliance evidence (SOUP register signed at every build + requirements→code→test traceability) that feeds BOTdesign's IEC 62304/MDR technical file. That directly offloads the regulated-software burden Fraysse's small, pharma-led team is otherwise carrying alone while scaling. References CadSmile and SpeechLink show the model on French digital-health SaMD. (OmDev builds and produces evidence; it does not certify.)

---
**Sources:** https://botdesign.net/ · https://botdesign.net/en/contact-2/ · https://www.myfrenchstartup.com/fr/startup-france/197349/botdesign · https://www.entreprises-occitanie.com/actualites/toulouse-avec-botdesign-lintelligence-artificielle-simplifie-la-vie-des-medecins-et-des · https://botdesign.net/en/2022/09/12/press-release-october-2020/ · https://botdesign.net/en/heko-en/ · https://www.linkedin.com/in/dr-jean-louis-fraysse-botdesign/ · https://www.welcometothejungle.com/fr/companies/botdesign · GetYourJob company record (slug: botdesign, enriched 2026-05-09; active offer: Stage Dev FullStack e-Santé - Sept 2026)